Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
15 October 2024 - 9:00PM
Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a
significant milestone in its innovative Linebacker™ technology
platform. The Canadian Intellectual Property Office has issued
Canadian Patent #3,024,728 entitled “
Electrophilically
Enhanced Phenolic Compounds for Treating Inflammatory Related
Diseases and Disorders". This patent includes claims to
novel enhanced phenolic compounds and pharmaceutical compositions
as well as their uses in treating inflammatory related diseases.
The Linebacker™ technology is a platform of small molecule
compounds, which target key pathways in the inflammatory process,
potentially reducing inflammation and providing symptomatic relief
while reducing side effects often associated with traditional
anti-inflammatory medications.
This patent also employs a method of using a Linebacker™
formulation of novel compounds, with potential to inhibit the
inflammatory response and mitigate conditions such as arthritis,
asthma, and inflammatory bowel disease. This marks the first
Linebacker™ patent issued in Canada, emphasizing Impact
BioMedical’s commitment to discovering, developing, and patenting
unique technologies to address unmet needs in human healthcare. The
term of this Canadian patent will expire in May 2037.
Frank D. Heuszel, CEO of Impact BioMedical, commented, "The
Canadian Inflammatory Disease Treatment Market was estimated to be
$7B in 2022 according to Precedence research. This patent issuance
strengthens our growing IP portfolio and underscores the innovative
nature and commercial and therapeutic potential of our Linebacker™
technology.”
About Impact BioMedical Inc.:Impact BioMedical
Inc. (“IBO”) discovers, confirms, and patents unique science and
technologies resulting in new offerings in human healthcare and
wellness. Once available, IBO works closely with licensing,
co-development, joint ventures, and other relationships to bring
these offerings to market. For more information, visit Impact
BioMedical Inc. | Reverse Engineering Nature
(impactbiomedinc.com).
About Linebacker™ : Linebacker™ is a platform
of small molecule electrophilically enhanced polyphenol compounds
with potential application in oncology (solid tumors), inflammatory
disorders, and neurology. Polyphenols are substances found in many
nuts, vegetables, and berries. Linebacker™ compounds are modified
myricetin, which is a common plant-derived flavonoid. Linebacker™
down-regulates PIM (proviral integration site for Moloney murine
leukemia virus) kinase which plays a key role as an oncogene in
solid tumor cancers. Composition and method patents are issued for
Linebacker™ in the U.S. and other countries. Linebacker™ -1 and
Linebacker™ -2 compounds have been licensed to ProPhase
Laboratories for development and commercialization worldwide.
Linebacker™ is a trademark of Impact BioMedical Inc.
Safe Harbor Disclosure:This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. Readers are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date.
Investor Relations:info@impactbiomedinc.com
Impact Biomedical (AMEX:IBO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Impact Biomedical (AMEX:IBO)
Historical Stock Chart
From Dec 2023 to Dec 2024